Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world.
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.
Johnson & Johnson (NYSE: JNJ) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:00 p.m. (Eastern Time).
Jim Cramer expressed strong buying conviction for Netflix Inc. during Wednesday's Lightning Round on "Mad Money," as the streaming giant's shares traded near $934 amid broader tech market strength.
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc., Johnson & Johnson, and Salesforce, Inc., as well as two micro-cap stocks, Preformed Line Products Co. and Cooper-Standard Holdings Inc.
(BPT) - For more than a century, Johnson & Johnson has been synonymous with innovation in science and medicine by moving the needle in building a world where complex diseases are prevented and cured, treatments are smarter, and solutions are personalized and accessible. Inventions like robotic surgery, tissue engineering, and treatments for cancers and HIV have changed the world forever and improved the patient experience and health and care for all.
Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.
